Sinsin Pharmaceutical Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sinsin Pharmaceutical.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 33.3% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
What Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) 40% Share Price Gain Is Not Telling You
Jul 30Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues
Mar 20What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?
Mar 06Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?
Feb 08If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today
Jan 18We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability
Dec 25What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?
Nov 29In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinsin Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2024 | 105,730 | 3,984 | 3,432 | 6,893 | N/A |
6/30/2024 | 105,246 | 4,049 | 512 | 3,454 | N/A |
3/31/2024 | 103,826 | 4,314 | -885 | 4,279 | N/A |
12/31/2023 | 102,586 | 4,680 | -1,097 | 3,930 | N/A |
9/30/2023 | 100,691 | 4,899 | 5,134 | 7,689 | N/A |
6/30/2023 | 98,396 | 5,249 | 5,791 | 9,004 | N/A |
3/31/2023 | 96,259 | 4,683 | 4,581 | 5,641 | N/A |
12/31/2022 | 91,926 | 4,415 | 4,459 | 5,461 | N/A |
9/30/2022 | 87,295 | 4,267 | 2,383 | 4,351 | N/A |
6/30/2022 | 82,522 | 2,554 | 3,080 | 5,132 | N/A |
3/31/2022 | 76,934 | -202 | 2,541 | 4,319 | N/A |
12/31/2021 | 74,008 | -1,476 | -2,659 | 23 | N/A |
9/30/2021 | 72,585 | -2,848 | -3,550 | -803 | N/A |
6/30/2021 | 71,022 | -489 | -8,987 | -4,680 | N/A |
3/31/2021 | 68,078 | -1,239 | -14,286 | -6,745 | N/A |
12/31/2020 | 67,129 | 363 | -9,997 | 1,865 | N/A |
9/30/2020 | 66,188 | 1,695 | -10,475 | 4,032 | N/A |
6/30/2020 | 65,909 | 266 | -14,045 | -1,814 | N/A |
3/31/2020 | 67,120 | 2,086 | -11,368 | 761 | N/A |
12/31/2019 | 67,855 | 2,138 | -25,010 | -4,506 | N/A |
9/30/2019 | 67,066 | 2,857 | -34,063 | -7,127 | N/A |
6/30/2019 | 65,868 | 2,572 | -36,360 | -1,388 | N/A |
3/31/2019 | 64,679 | 2,998 | -35,520 | -47 | N/A |
12/31/2018 | 63,720 | 2,896 | -24,818 | 774 | N/A |
9/30/2018 | 62,879 | 2,910 | -14,364 | 2,254 | N/A |
6/30/2018 | 61,700 | 3,222 | N/A | 4,124 | N/A |
3/31/2018 | 61,001 | 3,425 | N/A | 4,088 | N/A |
12/31/2017 | 61,733 | 3,605 | N/A | 4,569 | N/A |
9/30/2017 | 61,370 | 4,079 | N/A | 3,678 | N/A |
6/30/2017 | 60,370 | 4,016 | N/A | 3,989 | N/A |
3/31/2017 | 59,926 | 4,472 | N/A | 3,135 | N/A |
12/31/2016 | 58,069 | 4,441 | N/A | 2,794 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A002800's forecast earnings growth is above the savings rate (2.7%).
Earnings vs Market: Insufficient data to determine if A002800's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A002800's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A002800's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A002800's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A002800's Return on Equity is forecast to be high in 3 years time